Juno Therapeutics, which is developing immunotherapies for lymphomas, leukemias and other cancers, announced terms for its IPO on Tuesday. The Seattle, WA-based company plans to raise $153 million by offering 9.3 million shares at a price range of $15 to $18. At the midpoint of the proposed range, Juno Therapeutics would command a fully diluted market value of nearly $1.5 billion, which would make it the largest biotech of 2014 by market cap.
Juno Therapeutics, which was founded in 2013, plans to list on the NASDAQ under the symbol JUNO. Morgan Stanley, J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal. It is expected to price during the week of December 15, 2014.
